phrykt

AbbVie Inc. (ABBV): who owns it and who trades it

As of Nov 16, 2026, ABBV insiders reported 7 open-market sales worth $30.8M and no purchases in the last 12 months, with 31% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jeffrey Ryan Stewart (Vice president), with $11.9M. 9 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AbbVie

From the latest filings

Overall: more selling than buying. Insiders and Congress mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ABBV

4,190 funds and institutions reported ABBV shares worth $335B at the end of Q2 2026, about 75% of the company. The largest holder is BlackRock, Inc. with 8.5%.

Funds and institutions (13F) 75%Everyone else 25%

10 largest owners, by share of the company

BlackRock, Inc.8.5%
Vanguard Capital Management LLC6.5%
State Street Corp4.7%
Vanguard Portfolio Management LLC2.7%
JPMorgan Chase & Co2.7%
Geode Capital Management, LLC2.7%
Morgan Stanley2.2%
Capital Research Global Investors1.7%
Norges Bank1.4%
Bank of America Corp1.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.149.49M8.46%$37.6B-1%
Vanguard Capital Management LLC115.40M6.53%$29B+0%
State Street Corp82.60M4.67%$20.8B+2%
Vanguard Portfolio Management LLC48.48M2.74%$12.2B-2%
JPMorgan Chase & Co47.86M2.71%$12.2B–
Geode Capital Management, LLC47.00M2.66%$11.8B+1%
Morgan Stanley38.90M2.20%$9.8B+2%
Capital Research Global Investors30.10M1.70%$7.6B-4%
Norges Bank25.55M1.45%$6.4B–
Bank of America Corp21.24M1.20%$5.3B-11%
FMR LLC (Fidelity)20.77M1.18%$5.2B-5%
Northern Trust Corp20.56M1.16%$5.2B-3%
Franklin Resources Inc19.93M1.13%$5B+37%
Capital World Investors19.18M1.09%$4.8B+21%
Goldman Sachs Group Inc16.29M0.92%$4.1B+8%
Capital International Investors15.64M0.89%$3.9B+8%
T. Rowe Price Associates14.75M0.83%$3.7B+13%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC14.27M0.81%$3.6B+1%
Charles Schwab Investment Management Inc12.91M0.73%$3.3B-0%
Bank of New York Mellon Corp12.85M0.73%$3.2B-3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ABBV insiders reported $0 of open-market purchases and $30.8M of sales. 31% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$30.8M
7 trades, 4 people
Sales under a 10b5-1 plan
31%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 12, 2026

Purchases and sales by month

$11.9M$11.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026Jeffrey Ryan StewartVice presidentSale40,619$293.60$11.9MForm 4
Aug 14, 2026Nicholas DonoghoeVice presidentSale32,710$250.00$8.2MForm 4
Mar 4, 2026David Ryan PurdueVice presidentSale5,230$233.56$1.2MForm 4
Mar 2, 2026Perry C SiatisVice presidentSale plan10,291$234.66$2.4MForm 4
Mar 2, 2026Perry C SiatisVice presidentSale plan2,600$235.26$612KForm 4
Mar 2, 2026Perry C SiatisVice presidentSale plan5,777$233.51$1.3MForm 4
Feb 25, 2026Perry C SiatisVice presidentSale plan22,381$230.00$5.1MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICER–$11.9MNov 9, 2026
Perry C SiatisEVP, GC AND SECRETARY–$9.5MMar 2, 2026
Nicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICER–$8.2MAug 14, 2026
David Ryan PurdueSVP, Controller–$1.2MMar 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ABBV short interest

Low short interest. 0.9% of ABBV shares are sold short: about 1 share in 112. Over the last 12 reports the number of shares short went down 30%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 15.81M ABBV shares were sold short, 0.9% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 4.77M shares, buying them all back would take about 3.3 trading days (days to cover).

Shares short, % of all shares

0.89%May 15Oct 301.39%

Days to cover

3.3May 15Oct 305.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202615.81M0.89%+1%4.77M3.3
Oct 15, 202615.58M0.88%-4%5.72M2.7
Sep 30, 202616.28M0.92%-16%3.94M4.1
Sep 15, 202619.49M1.10%-0%4.35M4.5
Aug 31, 202619.51M1.10%+7%4.43M4.4
Aug 14, 202618.30M1.04%-19%5.12M3.6
Jul 31, 202622.55M1.28%-0%5.67M4.0
Jul 15, 202622.63M1.28%+3%6.56M3.5
Jun 30, 202621.90M1.24%-7%12.55M1.8
Jun 15, 202623.45M1.33%+1%5.15M4.5
May 29, 202623.16M1.31%+3%5.42M4.3
May 15, 202622.59M1.28%+8%5.67M4.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded ABBV

Since Nov 17, 2024, 14 members of Congress reported 18 purchases and 17 sales of ABBV. The latest was a sale by Pete Sessions on Sep 14, 2026, reported Sep 18, 2026.

Purchases 18Sales 17

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 14, 2026Pete Sessions (R-TX)Sale$15K–$50KSelfSep 18, 2026Report
May 5, 2026Josh Gottheimer (D-NJ)Sale$1K–$15KJointJun 3, 2026Report
Mar 27, 2026Alan Armstrong (R-OK)Purchase$15K–$50KSelfJul 21, 2026Report
Dec 18, 2025Julie Johnson (D-TX)Sale$1K–$15KJointJan 15, 2026Report
Dec 8, 2025Julia Letlow (R-LA)Sale$1K–$15KSelfJan 13, 2026Report
Nov 13, 2025Julie Johnson (D-TX)Partial sale$1K–$15KJointDec 11, 2025Report
Oct 31, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseNov 21, 2025Report
Oct 30, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseNov 21, 2025Report
Oct 30, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseNov 21, 2025Report
Aug 22, 2025John Boozman (R-AR)Partial sale$1K–$15KJointSep 12, 2025Report
Aug 14, 2025Julie Johnson (D-TX)Partial sale$1K–$15KJointSep 11, 2025Report
Aug 11, 2025John Boozman (R-AR)Partial sale$1K–$15KJointSep 12, 2025Report
Aug 4, 2025Marjorie Greene (GA)Purchase$1K–$15KSelfAug 15, 2025Report
Jul 22, 2025Lisa C. McClain (R-MI)Partial sale$1K–$15KSpouseAug 13, 2025Report
Jul 22, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report
Jul 11, 2025Ritchie Torres (D-NY)Sale$1K–$15KSelfAug 20, 2025Report
Jun 17, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report
May 22, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointJun 11, 2025Report
May 15, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfJun 9, 2025Report
May 5, 2025Marjorie Greene (GA)Purchase$1K–$15KSelfMay 6, 2025Report
Apr 28, 2025Julia Letlow (R-LA)Purchase$1K–$15KSelfJan 13, 2026Report
Apr 17, 2025Josh Gottheimer (D-NJ)Sale$1K–$15KJointMay 14, 2025Report
Apr 17, 2025Jefferson Shreve (R-IN)Sale$50K–$100KSelfMay 8, 2025Report
Apr 8, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfMay 8, 2025Report
Apr 7, 2025Jared Moskowitz (D-FL)Purchase$1K–$15KSelfMay 9, 2025Report
Apr 3, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointMay 14, 2025Report
Apr 3, 2025Dwight Evans (D-PA)Partial sale$1K–$15KSelfApr 17, 2025Report
Apr 1, 2025Josh Gottheimer (D-NJ)Purchase$1K–$15KJointMay 14, 2025Report
Mar 17, 2025Marjorie Greene (GA)Purchase$1K–$15KSelfMar 19, 2025Report
Feb 25, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfMar 27, 2025Report
Feb 24, 2025Jefferson Shreve (R-IN)Purchase$50K–$100KSelfMar 9, 2025Report
Jan 24, 2025Julia Letlow (R-LA)Sale$1K–$15KSelfJan 13, 2026Report
Jan 15, 2025Jared Moskowitz (D-FL)Purchase$1K–$15KChildFeb 10, 2025Report
Jan 15, 2025Jared Moskowitz (D-FL)Purchase$1K–$15KSelfFeb 10, 2025Report
Dec 6, 2024Virginia Foxx (R-NC)Purchase$1K–$15KSelfJan 6, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

AbbVie company events

AbbVie filed 17 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026LeadershipJennifer L. Davis, a Class II director of AbbVie Inc., notified the Company’s Board of Directors, of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the… Filing
  2. Oct 30, 2026ResultsReleased financial results. Filing
  3. Oct 15, 2026LeadershipAbbVie Inc. expanded the size of its Board of Directors from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Filing
  4. Oct 5, 2026ResultsReleased financial results. Filing
  5. Sep 3, 2026AnnouncementShared information with investors. Filing
  6. Aug 18, 2026AnnouncementAbbVie Inc. completed its previously announced underwritten public offering of $500 million of its senior floating rate notes due 2028, $1 billion of its 4.500% senior notes due 2028, $1.25 billion of its 4.650% senior notes due 2030, $1.5 billion of its 4.875% senior notes due 2031, $1.25 billion… Filing
  7. Aug 5, 2026AnnouncementAbbVie Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein, pursuant to which AbbVie agreed… Filing
  8. Jul 31, 2026ResultsReleased financial results. Filing
  9. Jul 6, 2026ResultsReleased financial results. Filing
  10. Jun 22, 2026AnnouncementShared information with investors. Filing
  11. May 12, 2026VoteReported shareholder vote results. Filing
  12. Apr 29, 2026ResultsReleased financial results. Filing
  13. Apr 3, 2026ResultsReleased financial results. Filing
  14. Mar 4, 2026AnnouncementAbbVie Inc. completed its previously announced underwritten public offering of $750 million of its senior floating rate notes due 2028, $1.5 billion of its 3.775% senior notes due 2028, $1.25 billion of its 4.125% senior notes due 2031, $1.25 billion of its 4.400% senior notes due 2033, $1.5… Filing
  15. Feb 26, 2026AnnouncementAbbVie Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II therein, pursuant to which AbbVie agreed… Filing
  16. Feb 4, 2026ResultsReleased financial results. Filing
  17. Jan 7, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

How AbbVie makes money

United States brought in 76% of AbbVie's revenue ($46.6B of $61.2B) in 2025. Germany was next, at 3%.

By region, 2025

United States$46.6B · 76%
Other Countries$5.8B · 9%
Germany$1.7B · 3%
Japan$1.3B · 2%
Canada$1.2B · 2%
China$1B · 2%
France$806M · 1%
United Kingdom$626M · 1%
Spain$609M · 1%
Italy$580M · 1%
Brazil$478M · 1%
Australia$459M · 1%

From AbbVie's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 20, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money

AbbVie financials

Famous investors that hold ABBV

9 of the 50 well-known investors we track reported holding ABBV in their latest 13F filing. The largest position is Ken Fisher's, worth $2.6B.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Fisher · Fisher Asset ManagementQ3 202610.06M$2.6B0.8%+6%
Ken Griffin · Citadel AdvisorsQ3 2026609,263$159M0.1%-81%
Israel Englander · Millennium ManagementQ3 2026144,668$37.8M0.0%-90%
Larry Robbins · Glenview Capital ManagementQ3 2026124,770$32.6M0.6%-16%
Paul Tudor Jones · Tudor Investment CorpQ3 202663,912$16.7M0.1%New
Tom Russo · Gardner Russo & QuinnQ3 202612,410$3.2M0.0%No change
Bill Nygren · Harris Associates (Oakmark)Q3 20262,420$633K0.0%No change
Lee Ainslie · Maverick CapitalQ3 20261,018$266K0.0%New
Jeremy Grantham · GMOQ3 2026919$240K0.0%+4%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about AbbVie Inc. (ABBV) stock

Who owns the most ABBV stock?

The largest reported owner of AbbVie Inc. (ABBV) is BlackRock, Inc., with 8.5% of the company. In total, 4,190 funds and institutions reported holding ABBV at the end of Q2 2026, together about 75% of the shares. See the largest owners.

Are ABBV insiders buying or selling?

In the last 12 months, ABBV insiders reported no open-market purchases and 7 sales worth $30.8M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in ABBV?

As of Oct 30, 2026, 15.81M ABBV shares were sold short, 0.9% of the shares outstanding, up 1.5% from the report before. At the average daily volume of 4.77M shares, buying them all back would take about 3.3 trading days (days to cover). See the history.

Have members of Congress traded ABBV?

Yes. 14 members of Congress reported 18 purchases and 17 sales of ABBV since Nov 17, 2024. The latest was reported on Sep 18, 2026. See the trades.

How does AbbVie make money?

United States brought in 76% of AbbVie's revenue ($46.6B of $61.2B) in 2025. Germany was next, at 3%. See the full split.

Which famous investors hold ABBV?

9 of the 50 well-known investors we track reported ABBV in their latest 13F filing, including Ken Fisher, Ken Griffin, Israel Englander. The largest position is worth $2.6B. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.